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Abstract
Background: The club cell secretory protein (CC16) has anti-inflammatory and antioxidant effects, and low CC16
serum levels have been associated with both risk and progression of COPD, yet the interaction between smoking and
CC16 on lung function outcomes remains unknown.
Methods: Utilizing cross-sectional data on United States veterans, CC16 serum concentrations were measured by
ELISA and log transformed for analyses. Spirometry was conducted and COPD status was defined by post-bronchodilator FEV1/FVC ratio < 0.7. Smoking measures were self-reported on questionnaire. Multivariable logistic and linear
regression were employed to examine associations between CC16 levels and COPD, and lung function with adjustment for covariates. Unadjusted Pearson correlations described relationships between CC16 level and lung function
measures, pack-years smoked, and years since smoking cessation.
Results: The study population (N = 351) was mostly male, white, with an average age over 60 years. An interaction between CC16 and smoking status on FEV1/FVC ratio was demonstrated among subjects with COPD (N = 245,
p = 0.01). There was a positive correlation among former smokers and negative correlation among current or never
smokers with COPD. Among former smokers with COPD, CC16 levels were also positively correlated with years since
smoking cessation, and inversely related with pack-years smoked. Increasing CC16 levels were associated with lower
odds of COPD (ORadj = 0.36, 95% CI 0.22–0.57, Padj < 0.0001).
Conclusions: Smoking status is an important effect modifier of CC16 relationships with lung function. Increasing
serum CC16 corresponded to increases in FEV1/FVC ratio in former smokers with COPD versus opposite relationships
in current or never smokers. Additional longitudinal studies may be warranted to assess relationship of CC16 with
smoking cessation on lung function among subjects with COPD.
Keywords: COPD, CC16, Lung function, Former smokers
Background
Chronic obstructive pulmonary disease (COPD) is a significant public health problem affecting an estimated 384
million (11.7%) globally, and is a leading cause of death [1,
2]. COPD is an obstructive airway disease characterized
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by chronic inflammation, an altered inflammatory
response to respiratory insults such as cigarette smoke,
and structural changes eventually leading to air trapping and decreased lung function [1]. Smoking is the
primary environmental risk factor for developing COPD,
although several other exposures can also contribute
to disease risk such as air pollution and occupational
exposures. The Club Cell Secretory Protein (CC16) is a
pneumoprotein with anti-inflammatory and antioxidant
properties, and is an emerging biomarker for COPD [3–
5]. Low baseline serum CC16 levels have been associated
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with lung function deficits [6, 7], and incident COPD in
two large prospective cohorts [6]. A similar relationship
was observed in a meta-analysis of over 1,100 adolescents
from three birth cohorts, where low serum CC16 measured at ages 4–6 years was associated with a 68 mL deficit in FEV1 measured at age 8–16 years [6]. There is also
interest in exploring the potential therapeutic benefits of
supplementing CC16 in COPD patients based upon preliminary experimental evidence [8–10].
CC16 is almost exclusively produced by club cells and
other non-ciliated airway epithelial cells, making up 7%
of all proteins in bronchoalveolar lavage fluid (BALF) [4].
CC16 moves from the airway into circulation via passive transportation upon injury to the epithelium from
inhaled toxins such as cigarette smoke [11]. Acute exposure to cigarette smoke temporarily increases circulating
CC16, while chronic exposure to cigarette smoke is associated with decreased levels in serum and BALF [4, 11].
In addition, it has been consistently reported that serum
levels are lower in subjects with COPD compared to controls [4, 12–14]. Furthermore, in COPD, current smokers
have lower CC16 levels than former and never smokers
[13–15]. Among adults with COPD, lower serum CC16
levels have been associated with lung function decline
indicating accelerated disease progression [15, 16].
Although smoking history (pack-years) and smoking
status have been recognized as potential confounders
in analyses of CC16 and lung function, there remains
knowledge gaps in COPD populations. Namely, the relationships between CC16 and smoking status and smoking history, CC16 and lung function measures, and the
possible interaction between CC16 and smoking status
on lung function outcomes has not been fully described.
Moreover, the previously described protective effect of
CC16 on risk of COPD requires further validation. Therefore, the aims of this study were to (1) examine relationships between serum CC16 levels and COPD, pack-years
smoked, years since smoking cessation, and lung function
measures among adults with COPD, and (2) determine if
there is an interaction between CC16 level and smoking
status related to lung function outcomes in adults with
COPD.

least 2 years of work experience on a farm as an adult,
and were between the ages 40–80 years. Veterans were
excluded if they had been diagnosed with asthma, lung
cancer or interstitial lung disease. Data collection has
been described elsewhere [18] and briefly, demographic
and clinical information was obtained from all participants at enrollment and included a questionnaire, blood
sample, and spirometry testing to assess lung function.
COPD was defined according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) standard
criteria as a post-bronchodilator ratio of forced expiratory volume released in 1 s (FEV1) to forced vital capacity (FVC) < 0.70 [1]. COPD subjects were recruited at a
stable state (i.e. no history of exacerbations or infection
in the previous 3 weeks before enrollment). Controls
were participants without COPD (i.e. pre-bronchodilator
FEV1/FVC ≥ 0.70) that had never smoked. COPD stage
was defined by the GOLD criteria (stage I–IV) [1]. The
analytical sample included 351 participants, including
245 COPD and 106 control subjects (never smokers).
This study was approved by the VA Nebraska Western
Iowa Healthcare Systems Institutional Review board and
a signed, written informed consent document was collected from all participants.

Methods

Other variable definitions

Study population

Smoking status was defined as current, former, or never
using the question, “Have you smoked a total of 100 cigarettes or more during your lifetime?”. Current smokers
were defined by the response, “Yes, and I still smoke”,
former smokers responded, “Yes, but I no longer smoke”,
and never smokers answered, “No, I never smoked.”
Pack-years smoked was calculated for current and former smokers. For current smokers, we used the equation (number of cigarettes smoked per day/20 cigarettes

The present study utilized data from a cross-sectional
study designed to investigate agricultural exposures and
chronic respiratory diseases among United States veterans. The study population has been described in more
detail elsewhere [17] but in brief, veterans visiting a primary care outpatient clinic at the VA Nebraska Western Iowa Health Care System between March 2008 and
December 2013 were eligible for the study if they had at

CC16

CC16 protein concentration was measured in serum
from stored samples using commercially available
enzyme-linked immunosorbent assay (ELISA) kits from
Bio Vendor (Asheville, NC; lower limit of detection
46 pg/mL). The distribution of serum CC16 levels were
right skewed, and therefore levels were log transformed
for analysis to approximate a normal distribution.
Lung function measures

Lung function was evaluated by spirometry in all participants. Post-bronchodilator spirometry was performed
if the ratio FEV1/FVC was < 0.70 (two doses of 0.083%
albuterol) [18]. FEV1 and FVC values were analyzed as
percentage of predicted value for specific sex, age, height,
weight (FVC only) and race according to NHANES III
reference equations [19].
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per pack) × (current age − age first started smoking
regularly), and the following equation for former smokers (number of cigarettes smoked per day/20 cigarettes
per pack) × (age last smoked regularly − age first started
smoking regularly). Among former smokers, the variable
‘time since quit smoking’ was defined by taking the difference between age last smoked regularly and current
age, both self-reported on the questionnaire. Therefore,
the ‘time since last smoked’ regularly (at least 3 cigarettes/week for at least 6 months or more) measurement
provides an estimate of the duration of smoking cessation
(in years).
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Table 1 Characteristics of study population stratified by COPD
vs controls (never smokers) N = 351

Age (years), mean (SD)

COPD
N = 245

Control subjects p
(never smokers)
N = 106

66.5 (8.3)

62.7 (9.5)

< 0.001

102 (96.2%)

0.07

Sex, N (%)
Male
Female

240 (99.2%)
2 (0.8%)

4 (3.8%)

Race, N (%)
White

234 (97.1%)

Other

7 (2.9%)

103 (97.2%)

0.97

3 (2.8%)

Education, N (%)

Statistical analysis

≤ High school

123 (52.1%)

34 (32.7%)

Descriptive statistics were used to summarize demographic and clinical characteristics of the study population. Visualizations display the median and interquartile
range for serum CC16 levels by COPD status, smoking
status, and GOLD stage. Student’s t-test and ANOVA
were used to evaluate associations between the log CC16
level and COPD, and GOLD stage. Linear regression was
employed to assess trends in log CC16 level by smoking status (never, former, current). Covariates included
the following: age (years, continuous), body mass index
(BMI) kg/m2 (continuous), smoking status (never, former,
current), pack-years (current and former smokers), assay
plate number (categorical), and systemic (i.e. prednisone)
or inhaled steroid use in the past 12 months. Pearson
correlations were used to examine relationships between
log CC16 and each lung function measure. Logistic
regression was used to evaluate relationships between
COPD and CC16 levels with controls being never smokers. Linear regression models were fit to assess relationships between log CC16 level, and lung function
measures adjusted for covariates. A multiplicative interaction term between log CC16 level and smoking status
was evaluated in each lung function model. An alternative analysis was performed treating smoking status as a
confounder in the model estimating the odds of COPD. A
p-value < 0.05 was considered statistically significant. SAS
9.4 was used for all analyses.

> High school

113 (47.9%)

70 (67.3%)

Results
Demographic and clinical characteristics of the study
population stratified by COPD status are described in
Table 1. COPD subjects were slightly older and less educated than control subjects (never smokers). Both groups
were predominately white, male, with an average age over
60 years. Among cases, 30.2% were current smokers,
61.2% former smokers, and 8.7% never smokers. Additionally, more than half (53.3%) were COPD GOLD stage
II, and only 6.2% had advanced stage disease (GOLD
stage IV), 18.4% took a prescribed inhaled steroid, and

BMI (kg/m2), median
(IQR)

29.0 (25.4–33.5) 32.5 (28.2–35.7)

0.001
< 0.0001

Smoking status, N (%)
Current

73 (30.2%)

–

Former

148 (61.2%)

–

Never

21 (8.7%)

106 (100.0%)

Pack-yearsa, median (IQR)

34.0 (13.0–56.0) 0 (0.0)

–

FEV1 (% predicted), mean
(SD)

65.4 (20.5)

89.8 (16.2)

< .0001

FVC (% predicted), mean
(SD)

83.0 (18.7)

86.7 (15.5)

0.07

FEV1/FVC, mean (SD)

57.7 (11.0)

77.9 (4.7)

< .0001

COPD GOLD stage, N (%)
I

62 (25.6%)

–

II

129 (53.3%)

–

III

36 (14.9%)

–

IV

15 (6.2%)

–

FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEV1/FVC: the
ratio of FEV1 to FVC; COPD: chronic obstructive pulmonary disease defined as
FEV1/FVC < 0.7; COPD GOLD stage: chronic obstructive pulmonary disease global
initiative for chronic obstructive lung disease stage; BMI: body mass index (kg/
m2); IQR: interquartile range = (25th percentile–75th percentile); SD: standard
deviation
a

Pack-years smoked calculated among former and current smokers only

9.8% took systemic steroids (i.e. prednisone) in the past
year.
Serum CC16 levels were significantly lower (p = 0.002)
among those with COPD (median 8.4 ng/mL) compared to controls (never smokers, median 10.2 ng/mL)
(Fig. 1A). Figure 1B depicts the unadjusted and adjusted
relationships between CC16 level (log) and COPD, demonstrating that CC16 level (log) was an independent
predictor of COPD after controlling for age, assay plate
number, and BMI (adjusted odds ratio = 0.36, 95% Confidence Interval [CI] 0.22–0.57, Padj < 0.0001). Another
analysis was performed estimating odds of COPD vs all
controls and adjusting for smoking status as a confounder
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Fig. 1 Serum CC16 levels are inversely associated with COPD. A Bar
graph depicts the median and interquartile range (IQR) of serum
CC16 levels (ng/mL) by COPD status (N = 351). Cases had significantly
lower levels of CC16 as compared to controls (never smokers) (t-test
using log CC16, p = 0.002). B Odds ratio plot displays the unadjusted
and model-adjusted association (odds ratios and 95% confidence
intervals) between log CC16 level and COPD vs control (never
smokers). Multivariable logistic regression model was adjusted for
age, assay plate number, and BMI. Odds of COPD decreased as serum
CC16 level (log scale) increased (ORadj = 0.36, 95% CI 0.22–0.57)
Padj < 0.0001 (N = 351)
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in the model along with other covariates (see Additional
file 1: Table S3). The strength of CC16 as a predictor
approached significance (adjusted odds ratio = 0.71, 95%
CI 0.5, 1.0, Padj = 0.06).
Serum CC16 levels did not vary significantly by COPD
GOLD Stage (P = 0.25) (Fig. 2A). Descriptively, CC16
levels were highest in COPD GOLD stage I (11.0 ng/
mL) in comparison to stage II (7.4 ng/mL), and stage III/
IV (8.3 ng/mL). There was a weak, but statistically significant, positive correlation between CC16 level and
the FEV1/FVC ratio in COPD (scatter plot, Fig. 2B). This
relationship persisted after adjustment for potential confounders (assay plate number, inhaled steroids, systemic
steroids, age, pack-years, smoking status, and BMI; see
Fig. 2B and Additional file 1: Table S1). Correlations with
CC16 levels were not distinguishable from zero for FEV1
percent predicted (r = 0.12, p = 0.07) or FVC percent
predicted (r = 0.02, p = 0.77). However, in multivariable
linear regression modeling, CC16 was associated with
FEV1 percent predicted (p = 0.03; see Additional file 1:
Table S1).
The distribution of serum CC16 level by smoking status among COPD cases is illustrated in Fig. 3A. Serum
CC16 levels in COPD were highest among never smokers (14.1 ng/mL), followed by former (9.2 ng/mL),
and then current smokers (6.6 ng/mL) (P for trend
unadjusted < 0.0001).
We further investigated relationships between CC16
serum level and lung function measures stratified by

Fig. 2 CC16 levels are correlated with FEV1/FVC within COPD subjects (N = 245). A A box and whisker plot depicts distribution of serum CC16 level
across COPD GOLD stages. The median is represented by a solid line and the box represents the interquartile range, whiskers are the minimum and
maximum values. There is no difference by stage (ANOVA test using log CC16 level by GOLD stages, p = 0.25). B Scatter plot depicts a weak positive
correlation between FEV1/FVC and log CC16 level in subjects with COPD (r = 0.15, p = 0.02). Adjusted p-value from multiple linear regression model
included the following covariates: age, pack-years, smoking status (current, former, never), assay plate number, BMI, and inhaled and systemic
steroid use. r = Pearson correlation coefficient
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Fig. 3 CC16 levels vary by smoking status in COPD (left); CC16 levels are positively correlated with FEV1/FVC among former smokers with COPD
(right). A A box and whisker plot depicts distribution of CC16 level across smoking status. The median is represented by a solid line and the box
represents the interquartile range, whiskers are the minimum and maximum. Serum CC16 levels in COPD were highest among never smokers,
followed by former and current (N = 245, P for trend < 0.0001). B A scatter plot depicts a positive correlation between CC16 level (log) and FEV1/FVC
among former smokers with COPD (N = 148, p = 0.0009). r = Pearson correlation coefficient

smoking status in those with COPD. A positive correlation (r = 0.27, p = 0.0009) was observed between FEV1/
FVC and serum CC16 levels among former smokers with
COPD (Fig. 3B). Although not distinguishable from zero,
negative correlations between FEV1/FVC ratio and CC16
serum level were found for current (N = 73, r = − 0.14,
p = 0.24) and never smokers (N = 21, r = − 0.11, p = 0.62)
with COPD. The positive correlation among former
smokers and negative correlations among current and
never smokers with COPD suggests an interaction.
Indeed, the interaction between CC16 levels and smoking status in regards to FEV1/FVC ratio in COPD was
confirmed in a multivariable linear regression model
adjusted for potential confounders age, BMI, pack-years,
assay plate number, inhaled and systemic steroid use
(padj = 0.01) (Fig. 4). Additional file 1: Table S2, details
the smoking status-stratified model output for the relationship between serum CC16 levels and FEV1/FVC
ratio. CC16 levels were also correlated with FEV1 percent
predicted among former smokers with COPD (r = 0.22,
p = 0.009). No additional relationships between CC16
level and lung function measures were demonstrated
within smoking status groups among those with COPD.
Next, we explored relationships between CC16 and
smoking history in COPD subjects. Among former smoking adults with COPD, there was an inverse relationship
between serum CC16 levels and pack-years (p = 0.03),
while no correlation was found for current smokers with
COPD (Fig. 5A). Furthermore, a positive correlation

was found between years since last smoked and CC16
serum level among former smokers with COPD (r = 0.4,
p < 0.0001) (Fig. 5B), suggesting a potential recovery of
serum CC16 level response over time following smoking cessation. The median time in cessation among former smoking COPD subjects was 11 years, with only 13
(8.8%) reporting a cessation period of less than 1 year.

Discussion
CC16 is an anti-inflammatory and antioxidant protein
in which low serum levels are associated with COPD.
In this current study, we confirmed the relationship of
low serum CC16 levels in COPD and importantly, demonstrated a novel interaction between smoking status
and serum CC16 level on lung function in subjects with
COPD. Former smoking, as opposed to current or never
smoking, was uniquely associated with lung function as
evident by the positive and linear relationship between
CC16 serum level and FEV1/FVC ratio in former smokers with COPD. Furthermore, serum levels of CC16 positively correlated with duration since quitting smoking,
indicating that the reduced serum CC16, presumably
induced by cigarette smoke exposure, is reversible, and
suggests that CC16 levels may ultimately recover after
smoking cessation among COPD subjects.
There has previously been limited evidence of the
effects of serum CC16 level on lung function measures
among former smokers, analyzed separately from current
smokers, within COPD populations. In the Evaluation of
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Fig. 4 Relationship between FEV1/FVC and CC16 level is modified by smoking status among those with COPD (N = 245). The linear regression
interaction plot depicts the statistically significant interaction effects between log CC16 level and smoking status on FEV1/FVC in COPD
(Pinteraction = 0.01). Presented are regression lines and 95% confidence intervals of the model estimated slopes for each smoking status calculated at
fixed values of other variables in the model. For former smokers with COPD, FEV1/FVC increased with each unit increase in log CC16 level, while an
inverse relationship was noted for never and current smokers with COPD. Along with the dependent variable, the model included the interaction
term (CC16 * smoking status), the main effects of smoking status and log CC16 level, age, BMI, pack-years, assay plate number, and inhaled and
systemic steroid use

Fig. 5 Correlations between CC16 level and pack-years smoked (former and current smokers with COPD) and years since last smoked (former
smokers) with COPD. A Scatter plot demonstrates correlations between CC16 level (log), and pack years smoked for current (N = 73) and former
smokers (N = 148) with COPD. There is no statistically significant correlation between serum CC16 levels and pack-years smoked among current
smokers with COPD (p = 0.66). There is a significant inverse relationship between pack-years smoked and CC16 levels among former smokers with
COPD (r = − 0.2, p = 0.03); CC16 levels decline as pack-years smoked increase. B Scatter plot depicts serum CC16 levels are positively correlated with
years since last smoked among former smokers with COPD. r = Pearson correlation coefficient

COPD Longitudinally to Identify Predictive Surrogate
Endpoints (ECLIPSE) COPD cohort, there was a weak
correlation between FEV1 and CC16 serum level among

former smokers (r = 0.11, p = < 0.001), and a non-statistically significant correlation among current smokers
(r = − 0.07, p = 0.069) in a combined sample of subjects
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with and without COPD (n = 1042 current smokers,
n = 1237 former smokers, n = 201 non-smoking controls)
[13]. Our findings are consistent with the ECLIPSE findings in that former smokers with COPD had decreased
CC16 levels, but in comparison, the strength and direction of the correlations with lung function within COPD
were more robust. In contrast, there was no association
between CC16 levels and FEV1/FVC ratio among current
or never smokers with COPD by stratified analysis in our
cohort. A potential explanation is that current smoking
is known to suppress CC16 expression and associated
circulating levels due to the Club cells’ role in detoxifying inhaled xenobiotics [3, 14, 15, 20]. COPD subjects
that continue to smoke after diagnosis experience more
rapid disease progression (i.e. loss of lung function over
time) compared to those that quit smoking. Therefore,
CC16 may have an essential role in multiple pathways
such as mediating smoke-induced lung injury, regulating inflammatory pathways, and/or structural damage
(emphysema). Serum CC16 levels were not associated
with FEV1/FVC ratio among never smokers with COPD
to highlight the relationship of cigarette smoke exposure
on epithelial cell CC16 expression [3]. The time course to
recovery of CC16 responses or whether CC16 levels ever
return to normal homeostasis in COPD subjects with
smoking history remains unknown.
Serum CC16 levels were positively correlated with
lung function (FEV1/FVC ratio) regardless of smoking status in COPD subjects, a finding consistent with
previous literature [14]. Namely, Rong and colleagues
investigated 98 COPD subjects that were defined as
47% smokers, without delineation of former vs. current
smoking status, and demonstrated a positive correlation
between CC16 and FEV1/FVC among COPD subjects
(r = 0.39, p = 0.002) [14]. Whereas we found a relationship between FEV1 percent predicted and CC16 level
among subjects with COPD in this cross-sectional study,
others have suggested that CC16 may be a biomarker
of COPD progression (decrease in FEV1 over time) [15,
16]. Using longitudinal data collected over three years on
2163 moderate-severe (GOLD stages II, III, IV) COPD
subjects within the ECLIPSE study population, it was
demonstrated that a one standard deviation decrease
in baseline CC16 level was associated with a 4 mL/year
greater rate of decline in FEV1 [16]. Park et al., confirmed these findings using 9-years of follow-up data
from the Lung Health Study participants with COPD
(N ~ 4700) reporting an inverse relationship between
CC16 level broken into quintiles (quintile 1 lowest CC16
level to quintile 5 highest) and rate of FEV1 decline [15].
Compared with the highest CC16 level (quintile 5), the
rate of decline in FEV1 ranged from 7 mL/year for lowest quintile to 0.88 mL/year in quintile four [15]. In the
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smoking-stratified analysis, the correlation between
CC16 level and FEV1 decline was only observed among
intermittent quitters as opposed to former smokers or
non-smokers [15]. In contrast, Celli and others reported
no correlation between CC16 levels and FEV1 percent
predicted or decline using Study to Understand Mortality
and MorbidITy (SUMMIT) randomized controlled trial
data on 1673 COPD subjects with increased cardiovascular disease risk [21]. Although, the authors acknowledged
CC16 levels were affected by treatment assignment, and
relationships were not adjusted for smoking [21]. Due to
the heterogenous nature of COPD, variability in CC16
levels, smoking status/history, and changes to lung function over time with aging, medication, or disease progression, additional longitudinal studies in larger COPD
cohorts are needed to better understand time-varying
and dynamic relationships between CC16 levels, smoking
status, and lung function in COPD populations.
CC16 protein is the primary product secreted by Club
cells which are present throughout the respiratory epithelium [11]. Club cells play a key role in host defense
through the expression of genes involved in immune,
anti-protease, anti-bacterial, and physical barrier function [22]. Cigarette smoke exposure directly damages
the club cells reducing their abundance, differentiation,
biological defense functions, and increases number of
mucous-producing cells [3, 8, 11, 22]. As such, smokeinduced injury to club cells and subsequent decreased
CC16 may contribute to an increased susceptibility to COPD [12]. In addition to smoke-induced loss of
club cells reducing levels of CC16 protein, the gene
(SCGB1A1) has been shown to be hypermethylated in
the small airway epithelium of healthy smokers compared to non-smokers which may lead to a reduction in
gene expression [23]. In our study, serum CC16 levels
were inversely associated with odds of COPD, supporting the existing evidence of a protective effect of CC16
on COPD risk [6, 12]. After disease onset, smoking status
and history affect CC16 levels. Confirmed in our study
and previously described, current smokers had the lowest serum levels of CC16, followed by former, and never
smokers with COPD [13–15]. The positive relationship
between CC16 and lung function among former smokers with COPD (and not in current or never smokers) is
supported by experimental evidence suggesting a role for
CC16 in regulating cigarette smoke-induced lung injury
in COPD [3, 10, 12].
While lung function in COPD is thought to be influenced by multiple factors including chronic inflammation, ongoing deleterious structural changes, and
overproduction of mucus leading to airway obstruction,
a complete understanding of mechanisms remains elusive [24]. Experimentally, cigarette-smoke exposed mice
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lacking CC16 have shown indications of lung injury
consistent with COPD pathologies [10, 12]. Utilizing a
mouse-model of COPD, mice that received intranasallyadministered recombinant CC16 experienced reductions in cigarette-smoked induced pro-inflammatory
cytokines (IL-6, IL-8, TNF-α), reduced NF-κB activation,
decreases in inflammatory cell infiltration, and reduced
alveolar size [10]. Our study supports that the magnitude
of smoking history, particularly in former smokers with
COPD, is important in CC16 responses because of the
inverse relationship found between the number of packyears smoked and serum CC16 level. Bernard and colleagues also reported that CC16 serum levels decreased
by an estimated 15% with each 10-pack-year unit increase
in healthy smoking adults [25]. A potential explanation
is serum CC16 expression following cessation in COPD
subjects may be partially determined by prior smoking
intensity (i.e. pack-years). Experimental data to support
these notions are currently lacking, but the smoke exposure “dose” could impact amount/degree of damage to
respiratory epithelium including the abundance of club
cells which secrete CC16 protein. This dose–response
relationship suggested by number of pack-years smoked
may not be demonstrated in current smokers with COPD
due to the ongoing smoke-exposure causing damage
to club cells and sustained suppression of CC16 in this
sample of current smokers with significant smoking history (average 35 pack-years). Whereas smoke exposure
induces long-lasting effects on club cells, this effect,
appears to be potentially reversible because we demonstrated increasing levels of CC16 with more time since
smoking cessation among former smokers with COPD.
This encouraging and novel observation requires further
investigation as strategies aimed at increasing effector
club cell numbers as well as club cell function that secrete
the anti-inflammatory/antioxidant CC16 protein may
represent novel approaches to reduce disease burden.
The association of serum CC16 level and COPD GOLD
stage is less clear. Rong and colleagues, noted a significantly lower CC16 level in COPD subjects with GOLD
stage III or IV compared with I or II [14]. In the ECLIPSE
study reported by Lomas and colleagues, there were no
differences in the serum CC16 levels by GOLD stage,
similar to our findings [13]. Lack of consensus is not surprising given heterogenous COPD study populations (e.g.
age, stage, definition of COPD) and variability of CC16
levels across studies. Disease progression and advancing stage is likely influenced by multiple factors that may
have varied across prior studies.
Our study has additional limitations. Due to the crosssectional design of this study, we cannot infer causality. While the finding of an interaction between CC16
and smoking status among COPD subjects was highly
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statistically significant, we acknowledge the number
of never smokers with COPD was small (N = 21) compared to former (N = 148) and current smokers (N = 73)
in the analysis likely due to most COPD cases resulting
from smoke exposure opposed to other factors that can
influence risk (i.e. occupational exposures, genetics).
Our cohort was limited to United States veterans in our
region that was predominately a male COPD population limiting generalizability. Study participants had at
least 2 years of farm exposure, and although we explored
but found no evidence of relationships between CC16
and agricultural exposures, it remains possible that agriculture exposures could affect serum CC16 levels, and
future studies to include agriculturally unexposed control groups would be warranted to fully understand this
relationship. This study did not have a validation cohort
which supports the need for evidence of CC16 and lung
function outcomes in independent COPD populations.
COPD subjects were recruited at a stable state, indicating no history of infection or exacerbation in the previous 3 weeks at the time of enrollment. However, time
from last exacerbation was not collected. The number
of COPD subjects with advanced disease (i.e. GOLD
stage III–IV) in our study population was relatively small
(n = 52) potentially prohibiting a complete evaluation of
CC16 levels by stage. There may also be differences in
smoking history or environmental exposure history from
military training and deployments between our sample
and other COPD populations. Lastly, we did not measure renal function to evaluate prevalence of chronic kidney disease which can influence CC16 concentrations
in serum (i.e. decreased renal clearance of CC16 would
elevate serum concentrations).

Conclusions
Our findings strongly support effect modification by
smoking status on the relationship between serum
CC16 level and lung function in COPD. We confirmed
that CC16 levels are lower in subjects with COPD and
current smokers with COPD, and importantly found
that with increasing CC16 levels in former smokers with COPD, FEV1/FVC ratio correspondingly
increased, which was not demonstrated in current
or never smokers with COPD. Although limited, the
existing mechanistic evidence supports these observations as Club cells, the respiratory cells responsible
for secreting CC16 protein, have a role in detoxifying
smoke/chemicals, thus rendering them susceptible
to damage resulting in reduced numbers and subsequently lower CC16 levels. After cessation, it is plausible Club cells and CC16 levels recover to a certain
degree, restoring CC16’s immunoregulatory functions
positively influencing lung function among COPD
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subjects. There is also potential for CC16 recovery
with post-smoking cessation that needs to be further
investigated as well as its role as a biomarker in COPD.
Understanding the role of CC16 in dynamics of COPD
and cigarette smoke interplay could also lead to new
therapeutic approaches to slow progression, or reverse
clinical disease course.
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